STAT+: How a four-month FDA delay forced a small biotech company to close its doors

Kezar Life Sciences, a small biotech firm, had to close after a four-month FDA delay in scheduling a critical clinical trial meeting for its treatment of autoimmune hepatitis. This incident highlights the significant risks small biotechs face due to regulatory inconsistencies and underscores the need for more predictable FDA processes to sustain innovation in rare disease treatments.

Read the full article at STAT News

---

Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.